HomeCompareNURO vs GBDC

NURO vs GBDC: Dividend Comparison 2026

NURO yields 43.67% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.49M in total portfolio value· pulled ahead in Year 5
10 years
NURO
NURO
● Live price
43.67%
Share price
$4.58
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$282.6K
Annual income
$51,335.69
Full NURO calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — NURO vs GBDC

📍 GBDC pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNUROGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NURO + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NURO pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NURO
Annual income on $10K today (after 15% tax)
$3,711.79/yr
After 10yr DRIP, annual income (after tax)
$43,635.34/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,887,238.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NURO + GBDC for your $10,000?

NURO: 50%GBDC: 50%
100% GBDC50/50100% NURO
Portfolio after 10yr
$10.53M
Annual income
$8,220,299.54/yr
Blended yield
78.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

NURO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-14.9
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NURO buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNUROGBDC
Forward yield43.67%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$282.6K$20.78M
Annual income after 10y$51,335.69$16,389,263.41
Total dividends collected$217.9K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: NURO vs GBDC ($10,000, DRIP)

YearNURO PortfolioNURO Income/yrGBDC PortfolioGBDC Income/yrGap
1$15,067$4,366.81$12,490$1,790.28+$2.6KNURO
2$22,270$6,148.97$16,522$3,157.73+$5.7KNURO
3$32,324$8,494.27$23,578$5,898.68+$8.7KNURO
4$46,108$11,522.15$37,115$11,886.75+$9.0KNURO
5← crossover$64,697$15,360.67$66,136$26,423.57$1.4KGBDC
6$89,369$20,143.18$137,257$66,491.44$47.9KGBDC
7$121,629$26,004.42$341,734$194,868.54$220.1KGBDC
8$163,219$33,076.14$1,050,788$685,133.02$887.6KGBDC
9$216,127$41,482.53$4,099,314$2,974,971.01$3.88MGBDC
10$282,592$51,335.69$20,775,530$16,389,263.41$20.49MGBDC

NURO vs GBDC: Complete Analysis 2026

NUROStock

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Full NURO Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this NURO vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NURO vs SCHDNURO vs JEPINURO vs ONURO vs KONURO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.